ATCC Announces New Award from BARDA to Join its Clinical Studies Network
Contract complements ATCC’s ongoing support of US COVID-19 pandemic response
Manassas, VA – October 6, 2020 – ATCC, the world’s premier biological materials management and standards organization, today announced a potential 10-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract award with a ceiling value of $250 million from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response with the Department of Health and Human Services (HHS).
This new contract complements ATCC’s ongoing support of the government’s COVID-19 pandemic response with BARDA, the National Institute of Allergy and Infectious Diseases, the Centers for Disease Control and Prevention, and the Food and Drug Administration. ATCC continues to fulfill its mission to bring standardization to biological material and investigational product management. In addition, this initiative provides new capabilities for the Clinical Studies Network (CSN) that will enhance continuity across the BARDA portfolio. The BARDA initiative will build on lessons-learned from ATCC’s existing contracts with the National Cancer Institute.
Specifically, ATCC will provide the BARDA CSN with a biological specimen and investigational product storage facility with centralized services for collection, receipt, storage, protection, processing, tracking, retrieval, packaging, and distribution. In this capacity, ATCC will provide a critical capability to the BARDA CSN, working in close coordination with other CSN components, including Clinical Trial Planning and Execution and the Statistical and Data Coordinating Center.
“This program enhances and extends ATCC’s long history as a national resource supporting both American competitiveness in basic and clinical science and critical public health efforts,” said Dr. Raymond H. Cypess, Chairman and CEO of ATCC. “ATCC is a partner in the investigations of the academic, government, and commercial research communities to develop effective diagnostic, therapeutic, and preventive tools and reagents. We look forward to supporting BARDA and the Clinical Studies Network to improve the health and safety of our nation.”
ATCC is honored to bring its demonstrated best practices for the safe and secure management of biological specimens to support BARDA’s mission by providing a central storage facility with standardized processes for inventory management, long-term storage of biological (clinical and/or non-clinical) specimens, and investigational products across BARDA-supported studies. ATCC also will manage transport of biological specimens and investigational products for end-of-study archiving and future use and will transfer legacy biological specimens and associated inventory data currently in temporary storage at contract research organizations.
“With this award, ATCC continues to expand its support for HHS and critical government clinical studies on vaccines, diagnostics, and therapeutics,” said Dr. Joseph Leonelli, Vice President of ATCC Federal Solutions. “We look forward to working on these important initiatives together.”
This content has been provided by ATCC
